Comment on PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia
AffiliationUniversity of Maryland; Imperial College London; Oregon Health and Science University; University of Chester; University of Michigan; University of Southern California; University of Navarra; MD Anderson Cancer Center; University of Newcastle
MetadataShow full item record
AbstractLB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.
CitationPerrotti, D., Agarwal, A., Lucas, C. M., Narla, G., Neviani, P., Odero, M. D., ... & Verrills, N. M. (2019). Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”. Science translational medicine, 11(501), eaau0416
JournalScience Translational Medicine
The following license files are associated with this item:
- Creative Commons